Relief Therapeutics is a Swiss, commercial-stage biopharmaceutical company developing and commercializing through selected partners novel, patent-protected therapies for specialty, rare, and ultra-rare diseases.
2025-08-14 05:01:09 https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/xml?limit=10&feed_template=news&page=1 https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/xml?limit=10&feed_template=news&page=2EQS Group 128 13 2025-08-14 07:00:07 2025-08-14 05:00:07 Europe/Berlin d1df0f96-080e-4cad-8b51-f4e2c4c80b50 d1df0f96-080e-4cad-8b51-f4e2c4c80b50-en adhoc en Relief Therapeutics Holding SA / Key word(s): Half Year Results
Relief Therapeutics Publishes 2025 Half-Year Report
14-Aug-2025 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.Relief Therapeutics Publishes 2025 Half-Year Report
GENEVA (AUG. 14, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the publication of its 2025 half-year report and provided a corporate update.
“Relief continued to make steady progress across our pipeline and corporate initiatives,” said Dr. Raghuram Selvaraju, chairman of the board of directors. “We advanced RLF‑TD011, our lead wound care candidate, with the receipt of Rare Pediatric Disease designation for epidermolysis bullosa and a productive Type B pre‑IND meeting with the FDA. We also progressed RLF‑OD032, our next‑generation liquid sapropterin formulation for phenylketonuria, toward a pivotal trial expected to begin this quarter. Our focus remains on advancing our core programs, with existing cash reserves projected to fund operations into at least late 2026, beyond the targeted regulatory submission of RLF‑OD032 for approval in the United States. In parallel, we are taking steps to establish a scalable, AI-driven health tech company through the proposed business combination with NeuroX.”
The report, available on the Company’s website, includes interim financial statements for the six months ended June 30, 2025, and a shareholder update.
ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief’s clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.comCONTACT
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.comDISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. In particular, there can be no assurance that the proposed business combination with NeuroX will be completed, as it remains subject to the execution of a definitive agreement, completion of satisfactory due diligence, and other conditions. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
Additional features:
File: Ad hoc
End of Inside Information
Language: English Company: Relief Therapeutics Holding SA Avenue de Secheron 15 1202 Geneva Switzerland Phone: +41 22 545 11 16 E-mail: contact@relieftherapeutics.com Internet: https://relieftherapeutics.com ISIN: CH1251125998 Valor: 125112599 Listed: SIX Swiss Exchange EQS News ID: 2183666
End of Announcement EQS News Service
2183666 14-Aug-2025 CET/CEST
]]>
https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/d1df0f96-080e-4cad-8b51-f4e2c4c80b50/html?lang=en&feed_template=news https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/d1df0f96-080e-4cad-8b51-f4e2c4c80b50/xml?lang=en&feed_template=news https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/d1df0f96-080e-4cad-8b51-f4e2c4c80b50/pdf?lang=en&feed_template=news https://eqs-cockpit.com/c/fncls.ssp?u=60083b3f0dcf7187be0dbf92e0a522ce&inline_display=1 2025-08-11 07:00:05 2025-08-11 05:00:05 Europe/Berlin 1626d798-6bc4-4fa2-87ff-09e00364f2ab 1626d798-6bc4-4fa2-87ff-09e00364f2ab-en corporate en Relief Therapeutics Holding SA / Key word(s): Half Year Results
Relief Therapeutics Advances Publication of 2025 Half-Year Report
11.08.2025 / 07:00 CET/CESTRelief Therapeutics Advances Publication of 2025 Half-Year Report
GENEVA (Aug. 11, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that it has advanced the publication date of its 2025 half-year report. Originally scheduled for release on August 27, 2025, the report will now be published on August 14, 2025, ahead of market opening.
The change in publication date is due to the Company’s anticipated early completion of the report. The half-year report, which will include a shareholder update and interim financial statements, will be available on Relief’s website at the time of publication.
ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief’s clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com
CONTACT
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.com
Additional features:
File: Press releaseEnd of Media Release
Language: English Company: Relief Therapeutics Holding SA Avenue de Secheron 15 1202 Geneva Switzerland Phone: +41 22 545 11 16 E-mail: contact@relieftherapeutics.com Internet: https://relieftherapeutics.com ISIN: CH1251125998 Valor: 125112599 Listed: SIX Swiss Exchange EQS News ID: 2181728
End of News EQS News Service
2181728 11.08.2025 CET/CEST
]]>
https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/1626d798-6bc4-4fa2-87ff-09e00364f2ab/html?lang=en&feed_template=news https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/1626d798-6bc4-4fa2-87ff-09e00364f2ab/xml?lang=en&feed_template=news https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/1626d798-6bc4-4fa2-87ff-09e00364f2ab/pdf?lang=en&feed_template=news https://eqs-cockpit.com/c/fncls.ssp?u=79813d1ad88e0b83442729e659a70af5&inline_display=1 2025-07-29 07:00:05 2025-07-29 05:00:05 Europe/Berlin 9548d12b-cfcf-4b8f-bbc7-1be9747675d5 9548d12b-cfcf-4b8f-bbc7-1be9747675d5-en adhoc en Relief Therapeutics Holding SA / Key word(s): Mergers & Acquisitions
Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze
29-Jul-2025 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze
- NeuroX recently acquired the assets and operations of MindMaze, a world-renowned leader in evidence-based neurotherapeutic solutions for neurological diseases and brain disorders
- Business combination to create an expanded, SIX-listed, commercial-stage, AI-driven, scalable health tech company
- Binding term sheet signed; transaction subject to customary conditions and approvals
- Closing expected in Q4 2025
GENEVA (July 29, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief” or the “Company”), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the execution of a binding term sheet for a proposed business combination with NeuroX Group SA (“NeuroX”), a privately held company that recently acquired the assets and operations of MindMaze – a recognized leader in digital neurotherapeutics and brain health technologies.
The envisaged combination aims to create a publicly listed, AI-based therapeutics platform integrating software-delivered, disease-modifying clinical interventions with pharmacological treatments and a comprehensive brain health platform to improve the quality of life of patients, caregivers and families. NeuroX will contribute a clinically validated, risk-mitigated portfolio supported by multiple milestones achieved across technological development, regulatory approvals, and market access, as well as a solid network of pharmaceutical partners.
Dr. Raghuram Selvaraju, chairman of the board of directors of Relief, commented: “By entering into this transaction, we intend to bring a global pioneer in digital neurotherapeutics to the public markets through the Relief ecosystem. NeuroX, which now operates the MindMaze platform, has a compelling business model, an established track record of innovation, and a distinctive technology that integrates neuroscience and digital therapeutics to address some of the most pressing challenges in neurology. We believe this combination has the potential to create significant value for patients, clinicians, and shareholders. Importantly, it offers existing Relief shareholders the opportunity to participate in the growth of a scalable enterprise with potential to become a multi-billion-dollar company.”
Alexandre Capet, head of corporate development of NeuroX, commented: “The business combination with Relief presents a timely opportunity to build on the vision and ambition set by MindMaze on a global scale, accelerating our market presence and next phase of growth. Over the past decade, we have built a robust portfolio of clinically validated digital neurotherapeutics and invested heavily in commercial infrastructure, AI technology, and R&D. With increased visibility and a solid foundation in place, we believe this transaction comes at a pivotal inflection point in our journey. It positions us to scale more effectively as a publicly listed company and expand the reach of our breakthrough therapies.”
NeuroX and MindMaze Overview
NeuroX is a Swiss-based, commercial-stage company. In 2025, NeuroX acquired the operations and intellectual property of the legacy MindMaze group (“MindMaze”), including the MindMaze® brand.MindMaze has developed first-of-its-kind neurotherapeutics that provide disease-modifying motor and cognitive treatments for neurological diseases and brain disorders. These neurotherapeutics are delivered through proprietary software and hardware, underpinned by an advanced brain technology platform that integrates wearables and sensors, and provides digital assessments as well as telehealth services. The unique suite of MindMaze solutions is delivered globally across the continuum-of-care, both in-clinic and in patients’ home, to successfully address some of neurology’s major unmet needs. NeuroX has already partnered with leading pharmaceutical companies that use its proprietary technology across multiple clinical trials.
Over the last decade, MindMaze has invested more than USD 350 million to establish clinical evidence, demonstrate significant medico-economic outcomes, and market MindMaze’s disease-modifying therapeutic platform across neurological diseases, including stroke, Parkinson’s disease, and at-risk aging. In the United States, MindMaze has received a unique reimbursement code (CAT-3) to support the delivery of its home-based neurotherapeutic training. Its R&D pipeline focuses on adjacent neurological diseases, such as spinal cord injury, multiple sclerosis, traumatic brain injury, and Alzheimer’s disease/dementia.
Moved by the mission to accelerate the brain’s ability to recover, the MindMaze platform innovates by combining software-delivered behavioral treatments, drugs, devices, data, and AI to establish a new paradigm of precision medicine in neurology and neural repair.
For more information, visit www.mindmaze.com.
Transaction Overview
Under the terms of the term sheet, NeuroX shareholders will exchange at closing all outstanding shares of NeuroX for newly issued shares of Relief. The transaction is based on agreed equity valuations of CHF 100 million for Relief, representing a significant premium to its current market capitalization, and CHF 1 billion for NeuroX. Post-closing, Relief shareholders are expected to own approximately 9% of the combined entity on a fully diluted basis, with NeuroX shareholders holding the remaining 91%. The combined entity’s shares will continue trading on the SIX Swiss Exchange.The term sheet provides for full exclusivity during the negotiation and finalization of a definitive agreement, as well as a customary break fee, reflecting the commitment of both parties to advance the transaction. It also includes a one-year post-closing reset mechanism to adjust the ownership ratio within certain parameters based on the combined entity’s market value at that time.
The transaction remains subject, among other customary conditions, to the negotiation and execution of a definitive agreement, completion of satisfactory due diligence, approval by the shareholders of both companies, completion of concurrent financing by NeuroX, filing of regulatory documentation with the applicable securities authorities, and receipt of regulatory and stock exchange approvals. There can be no assurance that the transaction will be completed on the terms described herein or at all.
The parties expect to finalize the definitive transaction agreement in Q3 2025, with closing anticipated in Q4 2025.
ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief’s clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. The Company has access to a CHF 50 million equity commitment in the form of a share subscription facility with its largest shareholder, Global Emerging Markets (GEM). For more information, visit www.relieftherapeutics.com.CONTACT
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.comDISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.The information provided on NeuroX and MindMaze within this press release is provided by NeuroX. Relief makes no representation or warranty as to the accuracy, completeness, or reliability of such information and disclaims any obligation or liability in connection with it.
No offer or solicitation: This press release does not constitute (i) a prospectus within the meaning of the Swiss Financial Services Act or under any other applicable laws, (ii) a solicitation of proxy, consent or authorization with respect to any securities or in respect of the proposed business combination or (iii) an offer to sell, a solicitation of an offer to buy, or a recommendation to buy any security of Relief, NeuroX, or any of their respective affiliates. There shall not be any sale of any securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the laws of such other jurisdiction. This press release should not be treated as offering material of any sort and is for information purposes only.
Additional features:
File: Ad hoc release
End of Inside Information
Language: English Company: Relief Therapeutics Holding SA Avenue de Secheron 15 1202 Geneva Switzerland Phone: +41 22 545 11 16 E-mail: contact@relieftherapeutics.com Internet: https://relieftherapeutics.com ISIN: CH1251125998 Valor: 125112599 Listed: SIX Swiss Exchange EQS News ID: 2175722
End of Announcement EQS News Service
2175722 29-Jul-2025 CET/CEST
]]>
https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/9548d12b-cfcf-4b8f-bbc7-1be9747675d5/html?lang=en&feed_template=news https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/9548d12b-cfcf-4b8f-bbc7-1be9747675d5/xml?lang=en&feed_template=news https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/9548d12b-cfcf-4b8f-bbc7-1be9747675d5/pdf?lang=en&feed_template=news https://eqs-cockpit.com/c/fncls.ssp?u=67707f8099a7880c88cb8491b86a469f&inline_display=1 2025-06-20 07:00:05 2025-06-20 05:00:05 Europe/Berlin 6c8c2c13-72c1-4bbc-8b89-372aee122e57 6c8c2c13-72c1-4bbc-8b89-372aee122e57-en adhoc en Relief Therapeutics Holding SA / Key word(s): Miscellaneous
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
20-Jun-2025 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
GENEVA (June 20, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that its initial request for Qualified Infectious Disease Product (QIDP) designation for RLF-TD011 for the treatment of epidermolysis bullosa (EB) was not granted by the U.S. Food and Drug Administration (FDA). The FDA determined that the investigational therapy does not currently meet the criteria for QIDP designation.
This outcome does not impact the Company’s development and regulatory strategy for RLF-TD011. The program continues to benefit from both Orphan Drug and Rare Pediatric Disease designations, which provide important regulatory and commercial incentives, including the potential for seven years of market exclusivity in the United States upon approval. RLF-TD011 is further supported by the Company’s intellectual property portfolio, including a recently granted European patent providing protection through 2040.
The Company also reported that it held a constructive pre-Investigational New Drug (pre-IND) meeting with the FDA. Discussions focused on the remaining clinical and regulatory steps required to advance RLF‑TD011 into later-stage development. Relief expects to complete the pre-IND meeting process upon receipt of the FDA’s written responses in the coming weeks.
ABOUT EPIDERMOLYSIS BULLOSA
Epidermolysis bullosa (EB) is a group of rare, inherited connective tissue disorders characterized by extreme skin fragility, leading to blistering and wounds from minor friction or injury. In severe cases, blisters can develop into chronic wounds or form in internal organs such as the mouth or esophagus, leading to painful wounds, recurrent infections, and a deeply impacted quality of life. EB is classified into several major inherited subtypes, each defined by the depth of blister formation within the skin’s layers: epidermolysis bullosa simplex (EBS), dystrophic epidermolysis bullosa (DEB), junctional epidermolysis bullosa (JEB) and Kindler syndrome (KS). Treatment is intensive and includes wound care, infection prevention, and pain management. Approximately 500,000 individuals worldwide are affected by EB.ABOUT RLF-TD011
RLF-TD011 is a highly pure, stabilized hypochlorous acid solution developed using Relief's proprietary TEHCLO™ technology. With strong antimicrobial properties, RLF-TD011 is a sprayable, self-administered solution for targeted wound application while avoiding skin contact and cross-contamination. Relief's acid-oxidizing solution has previously demonstrated efficacy in accelerating wound closure and reducing infections in certain clinical trials on non-EB wounds. In an investigator-initiated trial (NCT05533866), RLF‑TD011 has also shown promising results in infection control and wound healing in EB patients with the most severe forms of the disease. RLF-TD011 aims to address unmet needs in EB care by efficiently controlling infection and inflammation while reducing antibiotic use and easing the intensive, time-consuming wound care routine required by current treatments. The U.S. Food and Drug Administration has granted RLF-TD011 both Orphan Drug and Rare Pediatric Disease designations for EB.ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief’s clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.comCONTACT
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.comDISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
Additional features:
File: Ad hoc
End of Inside Information
Language: English Company: Relief Therapeutics Holding SA Avenue de Secheron 15 1202 Geneva Switzerland Phone: +41 22 545 11 16 E-mail: contact@relieftherapeutics.com Internet: https://relieftherapeutics.com ISIN: CH1251125998 Valor: 125112599 Listed: SIX Swiss Exchange EQS News ID: 2157876
End of Announcement EQS News Service
2157876 20-Jun-2025 CET/CEST
]]>
https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/6c8c2c13-72c1-4bbc-8b89-372aee122e57/html?lang=en&feed_template=news https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/6c8c2c13-72c1-4bbc-8b89-372aee122e57/xml?lang=en&feed_template=news https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/6c8c2c13-72c1-4bbc-8b89-372aee122e57/pdf?lang=en&feed_template=news https://eqs-cockpit.com/c/fncls.ssp?u=cc6c2d1f626121fcdd7e97acbb01c9cc&inline_display=1 2025-06-12 11:00:04 2025-06-12 09:00:04 Europe/Berlin 59000d91-29e8-406d-82d8-30a8aee50dfe 59000d91-29e8-406d-82d8-30a8aee50dfe-en corporate en Relief Therapeutics Holding SA / Key word(s): AGMEGM
Relief Therapeutics Announces Results of Annual General Meeting
12.06.2025 / 11:00 CET/CESTRelief Therapeutics Announces Results of Annual General Meeting
Shareholders approved all proposals by a large majority
GENEVA (June 12, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the results of its annual general meeting (AGM) of shareholders, held earlier today in Geneva. All proposed resolutions were approved by more than 85 percent of the represented votes.
AGM Results
- Annual Report and Financial Statements for the Year 2024
The AGM approved the 2024 annual report and financial statements.
- Appropriation of Available Earnings
The AGM approved carrying forward the net result for the 2024 financial year.
- Discharge of the Board of Directors and the Executive Committee
The AGM granted discharge to the board of directors and the executive committee for the 2024 financial year.
- Elections to the Board of Directors
The AGM re-elected Dr. Raghuram Selvaraju, Mr. Gregory Van Beek, Mr. Peter de Svastich, and Mr. Thomas Elzinga to the board of directors. Dr. Selvaraju was re-elected as chairman of the board. Mr. de Svastich and Dr. Selvaraju were re-elected as members of the nomination and compensation committee.
- Compensation of the members of the Board of Directors and of the Executive Committee
The AGM approved the proposed maximum compensation amounts for the board of directors for the period from AGM 2025 to AGM 2026, and for the executive committee for the 2026 financial year. Shareholders also approved, on a consultative basis, the 2024 compensation report.
- Independent Voting Rights Representative
The AGM re-elected Mr. Thomas Hua as the Company’s independent proxy.
- Auditors
The AGM re-elected FORVIS MAZARS SA as the Company’s statutory auditor.
The full text of the resolutions submitted to shareholders is available in the AGM Invitation. The detailed voting results will be published on the Company’s website later today.
ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief’s clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.comCONTACT
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.comDISCLAIMER
This press release may contain forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
Additional features:
File: Press release_Relief_2025 AGM ResultsEnd of Media Release
Language: English Company: Relief Therapeutics Holding SA Avenue de Secheron 15 1202 Geneva Switzerland Phone: +41 22 545 11 16 E-mail: contact@relieftherapeutics.com Internet: https://relieftherapeutics.com ISIN: CH1251125998 Valor: 125112599 Listed: SIX Swiss Exchange EQS News ID: 2153772
End of News EQS News Service
2153772 12.06.2025 CET/CEST
]]>
https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/59000d91-29e8-406d-82d8-30a8aee50dfe/html?lang=en&feed_template=news https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/59000d91-29e8-406d-82d8-30a8aee50dfe/xml?lang=en&feed_template=news https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/59000d91-29e8-406d-82d8-30a8aee50dfe/pdf?lang=en&feed_template=news https://eqs-cockpit.com/c/fncls.ssp?u=b1f56f1a1f9da7df288535e91ea11443&inline_display=1 2025-05-22 07:00:04 2025-05-22 05:00:04 Europe/Berlin 4fc37282-64af-4405-a2c6-f21c3bdaaabd 4fc37282-64af-4405-a2c6-f21c3bdaaabd-en adhoc en Relief Therapeutics Holding SA / Key word(s): Research Update
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
22-May-2025 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
GENEVA (May 22, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to RLF-TD011 for the treatment of epidermolysis bullosa (EB), a rare genetic skin disorder characterized by fragile skin and chronic wounds. The FDA had previously granted Orphan Drug Designation to RLF-TD011 for the same indication.
RLF-TD011 is a differentiated, hypotonic acid-oxidizing solution formulated with hypochlorous acid, designed to deliver potent antimicrobial and anti-inflammatory activity while creating a wound microenvironment conducive to healing. The Company previously reported promising clinical findings supporting RLF-TD011’s potential to meaningfully advance EB wound care by modulating the wound microbiome and reducing pathogenic colonization without disrupting beneficial bacteria.
“The FDA’s decision to grant Rare Pediatric Disease designation to RLF-TD011 underscores both the critical need for new options for patients living with EB and the potential of our investigational therapy,” said Giorgio Reiner, chief scientific officer of Relief. “We look forward to continued engagement with the FDA and to sharing the next steps in our development plan following our upcoming pre-IND meeting.”
The FDA grants RPD designation to product candidates targeting serious or life-threatening diseases that primarily affect individuals aged 18 years or younger and impact fewer than 200,000 people in the U.S. Companies that receive marketing approval for an RPD-designated indication may be eligible—subject to certain conditions, including congressional reauthorization of the program for designations granted after December 20, 2024—to receive a Priority Review Voucher (PRV), which grants expedited FDA review for a future marketing application. These vouchers are transferable; in May 2025, a PRV awarded following the approval of a treatment for a rare form of EB was sold for $155 million.
ABOUT EPIDERMOLYSIS BULLOSA
Epidermolysis bullosa (EB) is a group of rare, inherited connective tissue disorders characterized by extreme skin fragility, leading to blistering and wounds from minor friction or injury. In severe cases, blisters can develop into chronic wounds or form in internal organs such as the mouth or esophagus, leading to painful wounds, recurrent infections, and a deeply impacted quality of life. EB is classified into several major inherited subtypes, each defined by the depth of blister formation within the skin’s layers: epidermolysis bullosa simplex (EBS), dystrophic epidermolysis bullosa (DEB), junctional epidermolysis bullosa (JEB) and Kindler syndrome (KS). Treatment is intensive and includes wound care, infection prevention, and pain management. Approximately 500,000 individuals worldwide are affected by EB.ABOUT RLF-TD011
RLF-TD011 is a highly pure, stabilized hypochlorous acid solution developed using Relief's proprietary TEHCLO™ technology. With strong antimicrobial properties, RLF-TD011 is a sprayable, self-administered solution for targeted wound application while avoiding skin contact and cross-contamination. Relief's acid-oxidizing solution has previously demonstrated efficacy in accelerating wound closure and reducing infections in certain clinical trials on non-EB wounds. In an investigator-initiated trial (NCT05533866), RLF-TD011 has also shown promising results in infection control and wound healing in EB patients with the most severe forms of the disease. RLF-TD011 aims to address unmet needs in EB care by efficiently controlling infection and inflammation while reducing antibiotic use and easing the intensive, time-consuming wound care routine required by current treatments. The U.S. Food and Drug Administration has granted RLF-TD011 both Orphan Drug and Rare Pediatric Disease designations for EB, and Relief plans to seek Qualified Infectious Disease Product (QIDP) designation for extended market exclusivity.ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief’s clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.comCONTACT
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.comDISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
Additional features:
File: Ad hoc
End of Inside Information
Language: English Company: Relief Therapeutics Holding SA Avenue de Secheron 15 1202 Geneva Switzerland Phone: +41 22 545 11 16 E-mail: contact@relieftherapeutics.com Internet: https://relieftherapeutics.com ISIN: CH1251125998 Valor: 125112599 Listed: SIX Swiss Exchange EQS News ID: 2142942
End of Announcement EQS News Service
2142942 22-May-2025 CET/CEST
]]>
https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/4fc37282-64af-4405-a2c6-f21c3bdaaabd/html?lang=en&feed_template=news https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/4fc37282-64af-4405-a2c6-f21c3bdaaabd/xml?lang=en&feed_template=news https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/4fc37282-64af-4405-a2c6-f21c3bdaaabd/pdf?lang=en&feed_template=news https://eqs-cockpit.com/c/fncls.ssp?u=6327b68a2687d3b0dbd79f997d2eff50&inline_display=1 2025-05-15 07:00:05 2025-05-15 05:00:05 Europe/Berlin 1d831a11-e760-4002-bfef-4529b911449b 1d831a11-e760-4002-bfef-4529b911449b-en corporate en Relief Therapeutics Holding SA / Key word(s): AGMEGM
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
15.05.2025 / 07:00 CET/CESTRelief Therapeutics Publishes 2025 Annual General Meeting Agenda
GENEVA (MAY 15, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today published the agenda for its 2025 Annual General Meeting (AGM) of shareholders, to be held on June 12, 2025, at 10:00 a.m. CEST in Geneva, Switzerland.
The agenda includes approval of the 2024 annual report and financial statements, appropriation of available earnings, discharge of the board of directors and executive committee, re-election of the members of the board of directors and its chairman, re-election of the members of the nomination and compensation committee, and approval of the maximum compensation amounts for the board of directors and executive committee. Also included are a consultative vote on the 2024 compensation report and the re-election of the independent voting rights representative and auditors.
The formal notice of convocation of the AGM, including information regarding attendance in person or by proxy, notification and registration requirements, and ancillary documents relevant to the meeting, will be mailed to registered shareholders on May 21, 2025. The full agenda is available on the Relief website.
ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief’s clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.comCONTACT
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.comDISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
Additional features:
File: Press releaseEnd of Media Release
Language: English Company: Relief Therapeutics Holding SA Avenue de Secheron 15 1202 Geneva Switzerland Phone: +41 22 545 11 16 E-mail: contact@relieftherapeutics.com Internet: https://relieftherapeutics.com ISIN: CH1251125998 Valor: 125112599 Listed: SIX Swiss Exchange EQS News ID: 2137694
End of News EQS News Service
2137694 15.05.2025 CET/CEST
]]>
https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/1d831a11-e760-4002-bfef-4529b911449b/html?lang=en&feed_template=news https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/1d831a11-e760-4002-bfef-4529b911449b/xml?lang=en&feed_template=news https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/1d831a11-e760-4002-bfef-4529b911449b/pdf?lang=en&feed_template=news https://eqs-cockpit.com/c/fncls.ssp?u=e7567f3fdd3230d07d605d6d4871f4df&inline_display=1 2025-04-10 07:00:24 2025-04-10 05:00:24 Europe/Berlin 44f325b8-96d6-44ae-b05a-ceebaa05a0a6 44f325b8-96d6-44ae-b05a-ceebaa05a0a6-en adhoc en Relief Therapeutics Holding SA / Key word(s): Annual Results
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
10-Apr-2025 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
GENEVA (APR. 10, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today published its 2024 Annual Report and provided a corporate update.
In his annual letter to shareholders, Dr. Raghuram Selvaraju, chairman of the board of directors, emphasized the Company’s operational achievements, pipeline momentum, and strengthened financial position. “This past year, we built a stronger foundation and made measurable progress in executing our plans as we advanced our core pipeline and optimized our commercial strategy, always guided by our commitment to delivering meaningful solutions for patients with unmet medical needs,” said Dr. Selvaraju. “We are particularly excited by the continued progress of RLF-OD032, our next-generation liquid sapropterin formulation for phenylketonuria, and RLF-TD011, our proprietary hypochlorous acid solution for epidermolysis bullosa. We look forward to important clinical and regulatory milestones in 2025.”
Relief’s 2024 Annual Report, which includes pipeline and portfolio updates, corporate governance and compensation disclosures, and financial statements, is available on the Company’s website.
ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief’s clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.comCONTACT
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.comDISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
Additional features:
File: Ad hoc
End of Inside Information
Language: English Company: Relief Therapeutics Holding SA Avenue de Secheron 15 1202 Geneva Switzerland Phone: +41 22 545 11 16 E-mail: contact@relieftherapeutics.com Internet: https://relieftherapeutics.com ISIN: CH1251125998 Valor: 125112599 Listed: SIX Swiss Exchange EQS News ID: 2114490
End of Announcement EQS News Service
2114490 10-Apr-2025 CET/CEST
]]>
https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/44f325b8-96d6-44ae-b05a-ceebaa05a0a6/html?lang=en&feed_template=news https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/44f325b8-96d6-44ae-b05a-ceebaa05a0a6/xml?lang=en&feed_template=news https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/44f325b8-96d6-44ae-b05a-ceebaa05a0a6/pdf?lang=en&feed_template=news https://eqs-cockpit.com/c/fncls.ssp?u=9e357ebb03d10861c929664104d66ada&inline_display=1 2025-03-06 07:00:39 2025-03-06 06:00:39 Europe/Berlin 0e8308e2-ea54-4a26-99df-378bfe9b25e5 0e8308e2-ea54-4a26-99df-378bfe9b25e5-en adhoc en Relief Therapeutics Holding SA / Key word(s): Merger
Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion
06-March-2025 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion
GENEVA (March 6, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that discussions regarding a potential merger with Renexxion, Inc. (Renexxion) have been terminated.
After signing a non-binding letter of intent in November 2024, both companies engaged in discussions to form a combined entity with an expanded therapeutic pipeline. However, key conditions necessary to finalize the transaction were not met within the required timeframe. As a result, both parties have mutually agreed to discontinue negotiations.
“While we ultimately decided not to proceed with Renexxion, Relief remains well-positioned to advance its strategic objectives independently. In recent months, we have made meaningful progress across our core development programs and continue to build momentum. With a robust pipeline and around CHF 15 million in cash reserves, along with a CHF 50 million undrawn equity facility from our largest shareholder GEM, we are confident in our ability to execute our development strategy while continuing to explore opportunities to maximize shareholder value,” said Dr. Raghuram Selvaraju, chairman of the board of directors of Relief.
The Company also announced that it will provide a comprehensive business update in its 2024 Annual Report, scheduled for publication on April 10, 2025.
ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety, and convenience to benefit the lives of patients living with select specialty and rare diseases. Relief’s portfolio includes revenue-generating products, commercialized through licensing and distribution partnerships, and a targeted clinical development pipeline. Relief’s pipeline consists of risk-mitigated assets in three core therapeutic areas: rare skin diseases, rare metabolic disorders, and rare respiratory diseases. Key development programs include RLF-TD011, a stabilized hypochlorous acid solution designed to improve wound healing and infection control in epidermolysis bullosa, and RLF-OD032, a ready-to-use liquid formulation of sapropterin dihydrochloride aimed at enhancing treatment adherence in phenylketonuria patients. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com.CONTACT:
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.comDISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
Additional features:
File: Ad hoc
End of Inside Information
Language: English Company: Relief Therapeutics Holding SA Avenue de Secheron 15 1202 Geneva Switzerland Phone: +41 22 545 11 16 E-mail: contact@relieftherapeutics.com Internet: https://relieftherapeutics.com ISIN: CH1251125998 Valor: 125112599 Listed: SIX Swiss Exchange EQS News ID: 2096037
End of Announcement EQS News Service
2096037 06-March-2025 CET/CEST
]]>
https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/0e8308e2-ea54-4a26-99df-378bfe9b25e5/html?lang=en&feed_template=news https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/0e8308e2-ea54-4a26-99df-378bfe9b25e5/xml?lang=en&feed_template=news https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/0e8308e2-ea54-4a26-99df-378bfe9b25e5/pdf?lang=en&feed_template=news https://eqs-cockpit.com/c/fncls.ssp?u=55599b028131c67c8e0013c33c44b0dc&inline_display=1 2025-02-11 07:00:03 2025-02-11 06:00:03 Europe/Berlin 2a1c8670-0935-4c1a-bff9-db2df6ac1c65 2a1c8670-0935-4c1a-bff9-db2df6ac1c65-en corporate en Relief Therapeutics Holding SA / Key word(s): Patent
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
11.02.2025 / 07:00 CET/CESTRelief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
Patent Secures Protection for RLF-TD011 in Epidermolysis Bullosa Wound Treatment
GENEVA (FEB. 11, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced that the European Patent Office (EPO) has issued a Decision to Grant for its patent application titled “Therapeutic Uses of Oxidizing Hypotonic Acid Solutions.”
This patent will protect therapeutic applications of Relief’s proprietary, highly pure hypochlorous acid solutions, including its investigational drug RLF‑TD011 for the treatment of wounds caused by epidermolysis bullosa (EB) in key European countries.
The EPO is expected to formally issue the patent on February 26, 2025, under patent number EP 3993811. The patent will remain in effect until 2040, as anticipated by the Notice of Allowance received in October 2024. Corresponding patent applications are under review in other major markets, including the United States and China.
RLF-TD011 has previously received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of EB. The Company also intends to seek qualified infectious disease product (QIDP) designation from the FDA. These designations would provide potential incentives such as market exclusivity upon approval.
Relief continues to advance the development of its lead program and recently reported positive results from its investigator-initiated clinical trial evaluating RLF-TD011 for the treatment of EB. The Company is currently preparing a pre-IND meeting package for submission to the FDA to finalize the remaining clinical development and regulatory strategy for RLF-TD011.
ABOUT RLF-TD011
RLF-TD011 is a highly pure, stabilized hypochlorous acid solution developed using Relief's proprietary TEHCLO™ technology. With strong antimicrobial properties, RLF-TD011 is a sprayable, self-administered solution for targeted wound application while avoiding skin contact and cross-contamination. RLF-TD011 has demonstrated efficacy in accelerating wound closure and reducing infections in certain clinical trials on non-EB wounds. In an investigator-initiated trial (NCT05533866), RLF-TD011 has also shown promising results in infection control and wound healing in EB patients with the most severe forms of the disease. RLF-TD011 aims to address unmet needs in EB care by efficiently controlling infection and inflammation while reducing antibiotic use and easing the intensive, time-consuming wound care routine required by current treatments.ABOUT EPIDERMOLYSIS BULLOSA
Epidermolysis bullosa (EB) is a group of rare, inherited connective tissue disorders characterized by extreme skin fragility, leading to blistering and wounds from minor friction or injury. In severe cases, blisters can develop into chronic wounds or form in internal organs such as the mouth or esophagus, leading to painful wounds, recurrent infections, and a deeply impacted quality of life. EB is classified into several major inherited subtypes, each defined by the depth of blister formation within the skin’s layers: epidermolysis bullosa simplex (EBS), dystrophic epidermolysis bullosa (DEB), junctional epidermolysis bullosa (JEB) and Kindler syndrome (KS). Treatment is intensive and includes wound care, infection prevention, and pain management. Approximately 500,000 individuals worldwide are affected by EB.ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety, and convenience to benefit the lives of patients living with select specialty and rare diseases. Relief’s portfolio offers a balanced mix of marketed, revenue-generating products, proprietary, globally patented TEHCLO™ and Physiomimic™ platform technologies and a targeted clinical development pipeline consisting of risk-mitigated assets focused in three core therapeutic areas: rare skin diseases, rare metabolic disorders, and rare respiratory diseases. In addition, Relief is commercializing several legacy products via licensing and distribution partners. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com.CONTACT:
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.comDISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
Additional features:
File: Press ReleaseEnd of Media Release
Language: English Company: Relief Therapeutics Holding SA Avenue de Secheron 15 1202 Geneva Switzerland Phone: +41 22 545 11 16 E-mail: contact@relieftherapeutics.com Internet: https://relieftherapeutics.com ISIN: CH1251125998 Valor: 125112599 Listed: SIX Swiss Exchange EQS News ID: 2084023
End of News EQS News Service
2084023 11.02.2025 CET/CEST
]]>
https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/2a1c8670-0935-4c1a-bff9-db2df6ac1c65/html?lang=en&feed_template=news https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/2a1c8670-0935-4c1a-bff9-db2df6ac1c65/xml?lang=en&feed_template=news https://ir-api.eqs.com/feeds/news/c929bec5-e6e7-4dad-93e4-84080a95eff5/detail/2a1c8670-0935-4c1a-bff9-db2df6ac1c65/pdf?lang=en&feed_template=news https://eqs-cockpit.com/c/fncls.ssp?u=5342e575c23c09252493810b6a974011&inline_display=1
© Relief Therapeutics